It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile


call (888) 352-RUSH for help arranging an appointment

Jamile M. Shammo, MD

Patient Feedback
  • Hematology
  • Internal Medicine
  • Pathology-Anatomic/Pathology-Clinical
Board Certification:
  • Hematology
  • Pathology-Anatomic/Pathology-Clinical
Faculty Rank: Associate Professor
Medical or Graduate Education: Aleppo University School of Medicine, Syria
Residency: McGaw Medical Center of Northwestern University - Internal Medicine; Anatomic and Clinical Pathology
Fellowship: University of Chicago Medical Center - Hematology/Oncology
Clinical Expertise:
  • Anemia
  • Aplastic anemia
  • Myelodysplastic syndrome (MDS)
  • Myeloproliferative neoplasms
  • Paroxysmal nocturnal hemoglobinuria
Research Interests:
  • Myelodysplastic syndromes (MDS)
  • Myeloproliferative disorders
  • Chronic myelogenous leukemia (CML)
  • Aplastic anemia
  • Paroxysmal nocturnal hemoglobinuria ( PNH)
Languages Spoken:
  • Arabic
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

    Karmali R, Larson ML, Shammo JM, Basu S, Christopherson K, Borgia JA, Venugopal P
    Leuk. Lymphoma
    2015 Mar 4
  2. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera.
    Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR.
    Leuk Lymphoma. 2013
    2013 Jan 8. [Epub ahead of print]
  3. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes.
    Foran JM, Shammo JM.
    Am J Med. 2012
    2012 Jul
    125(7 Suppl):S6-13. doi: 10.1016/j.amjmed.2012.04.015. Review.
  4. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
    Gregory SA, Mesa RA, Hoffman R, Shammo JM.
    Clin Adv Hematol Oncol. 2011
    2011 Sep
    9(9 Suppl 22):1-16.
  5. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
    Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P.
    Leuk Lymphoma. 2011
    2011 Nov
    52(11):2097-104. doi: 10.3109/10428194.2011.589549. Epub 2011 Jun 24.
  6. An examination of educational gaps in the diagnosis and treatment of myelodysplastic syndromes.
    Shammo JM, Foran JM, Houk A, Epstein J, Narang M, Rubinstein P, Dennison B, Latsko JM, Naganna G.
    Cancer Control. 2011
    2011 Jan
  7. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA.
    Clin Lymphoma Myeloma Leuk. 2011
    2011 Dec
    11(6):467-74. doi: 10.1016/j.clml.2011.04.009. Epub 2011 Jun 22.
  8. Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).
    Cela I, Miller IJ, Katz RS, Rizman A, Shammo JM.
    Clin Adv Hematol Oncol. 2010
    2010 Nov
    8(11):806-9. No abstract available.
  9. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
    Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.
    J Clin Oncol. 2010
    2010 Jan 20
    28(3):437-44. doi: 10.1200/JCO.2009.24.7999. Epub 2009 Dec 14.
  10. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
    Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM.
    J Clin Oncol. 2010
    2010 Feb 20
    28(6):1038-46. doi: 10.1200/JCO.2009.25.4961. Epub 2010 Jan 19.
  11. Clinical roundtable monograph. MDS classification and risk stratification.
    Shammo JM.
    Clin Adv Hematol Oncol. 2009
    2009 Jul
    7(7):S8-12. No abstract available.
  12. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
    Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF
    2008 Jan 1
  13. Idiopathic hemophagocytic syndrome with a fulminant clinical course.
    Khandelwal A, Shah NB, Eichenseer P, Welker M, Miller I, Nangia J, Farhat M, Gimelfarb A, Kassar M, Batus M, Gezer S, Shammo J, Gregory S, Fung H, Venugopal P.
    Clin Adv Hematol Oncol. 2008
    2008 Aug
    6(8):587-90. Review. No abstract available.
  • To watch a brief video of Jamile M. Shammo, MD, click the play button at the lower left corner of the video frame below. (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript
Patient feedback information is available for physicians employed by Rush University Medical Center who have received 30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Number of Patient Surveys
Friendliness/courtesy of the care provider
Explanations the care provider gave you about your problem or condition
Concern the care provider showed for your questions or worries
Likelihood of your recommending this care provider to others
Care provider's efforts to include you in decisions about your treatment
Information the care provider gave you about medications
Instructions the care provider gave you about follow-up care
Your confidence in this care provider
Degree to which care provider talked with you using words you could understand
Amount of time the care provider spent with you
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.